Aisling Capital
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- USA
Investment stages
- Seed
- Series A
- Series B
- Series B
Industries
- Health Tech
- Bio Tech
- Digital Health
About
Aisling Capital is a leading institutional investment firm based in New York, United States. Established in 2000 with the aim of supporting the development and commercialization of important and innovative healthcare products, services, and technologies, Aisling Capital has built a notable portfolio that includes companies in the health tech and biotechnology sectors. Known for its expertise and a team with over 150 years of combined experience in the healthcare industry, Aisling Capital prides itself on a track record of successful investments and capital returns. They have raised over $1.8 billion in committed capital across four funds, investing in both private and public companies with a wide variety of investment structures. Aisling Capital has made 106 investments to date and takes an active approach, working closely with portfolio companies.
Aisling Capital is a leading institutional investment firm based in New York, United States. Established in 2000 with the aim of supporting the development and commercialization of important and innovative healthcare products, services, and technologies, Aisling Capital has built a notable portfolio that includes companies in the health tech and biotechnology sectors. Known for its expertise and a team with over 150 years of combined experience in the healthcare industry, Aisling Capital prides itself on a track record of successful investments and capital returns. They have raised over $1.8 billion in committed capital across four funds, investing in both private and public companies with a wide variety of investment structures. Aisling Capital has made 106 investments to date and takes an active approach, working closely with portfolio companies.
Investment Thesis
Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies. They seek to identify differentiated healthcare products, services and technologies that address unmet medical needs, and provide promising companies with meaningful capital resources.
Team
Steven Elms
Andrew Schiff
MD
Eric Aguiar
MD
Sunny Reddy
Wonpyo Yun
A.J. Sacks
Robert Wenzel
Katie Tansey
Hannah Wieder
Carol Zikopoulos
Dr. Josh Bilenker
Scott Braunstein
MD
Aftab Kherani
MD
Portfolio
Quintiles
Loxo
Biohaven
Harmony Biosciences
Zeltiq
Aimmune
Dren Bio
Verona Pharma
Tectonic Therapeutic
BridgeBio Oncology Therapeutics
Nuvation Bio
CalciMedica
Bicara Therapeutics
COMPASS Pathways
Aeglea BioTherapeutics
Adma Biologics
Elevation Oncology
Marker Therapeutics
Treeline Biosciences
Aclaris Therapeutics
Monte Rosa Therapeutics
BridgeBio Pharma
Invitae
Biomea Fusion
Garuda Therapeutics
PellePharm
Mindful Health Solutions
Wugen
Forge Biologics
Monte Rosa Therapeutics
Cortica
Ablacon
Protaryx
Serpex
Verix Health
Summus
Ajax Health
Arcus Biosciences
Spirox
Syros Pharmaceuticals
TransEnterix